120 related articles for article (PubMed ID: 22414039)
21. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
Boumis E; Chinello P; Della Rocca C; Paglia MG; Proietti MF; Petrosillo N
Int J STD AIDS; 2006 May; 17(5):351-3. PubMed ID: 16643688
[TBL] [Abstract][Full Text] [Related]
22. Side effects of treatment with antimony salts.
Malta R; Affronti M; Di Rosa S; Vassallo L; Renda M; Trifirò G; Rubino ME; Rini GB
J Chemother; 1989 Jul; 1(4 Suppl):628-9. PubMed ID: 16312564
[No Abstract] [Full Text] [Related]
23. Reduced tissue parasitic load and infectivity to sand flies in dogs naturally infected by Leishmania (Leishmania) chagasi following treatment with a liposome formulation of meglumine antimoniate.
Ribeiro RR; Moura EP; Pimentel VM; Sampaio WM; Silva SM; Schettini DA; Alves CF; Melo FA; Tafuri WL; Demicheli C; Melo MN; Frézard F; Michalick MS
Antimicrob Agents Chemother; 2008 Jul; 52(7):2564-72. PubMed ID: 18458133
[TBL] [Abstract][Full Text] [Related]
24. Acute renal failure due to visceral leishmaniasis by Leishmania infantum successfully treated with a single high dose of liposomal amphotericin B.
Beltrame A; Arzese A; Camporese A; Rorato G; Crapis M; Tarabini-Castellani G; Boscutti G; Pizzolitto S; Calianno G; Matteelli A; Di Muccio T; Gramiccia M; Viale P
J Travel Med; 2008; 15(5):358-60. PubMed ID: 19006511
[TBL] [Abstract][Full Text] [Related]
25. [Fever, pancytopenia, and splenomegaly 8 months after a trip to Majorca Island (Spain)].
Lübbert C; Opitz BM; Harms-Zwingenberger G; Nietsch HH
Med Klin (Munich); 2008 Jan; 103(1):29-35. PubMed ID: 18219460
[TBL] [Abstract][Full Text] [Related]
26. Mediterranean visceral leishmaniasis in pregnancy.
Gradoni L; Gaeta GB; Pellizzer G; Maisto A; Scalone A
Scand J Infect Dis; 1994; 26(5):627-9. PubMed ID: 7855563
[TBL] [Abstract][Full Text] [Related]
27. Risk factors associated with dizziness during treatment of mucosal leishmaniasis with meglumine antimoniate: 16-year retrospective study of cases from Rio de Janeiro, Brazil.
Araujo-Melo MH; Meneses AM; Schubach AO; Moreira JS; Conceição-Silva F; Salgueiro MM; Pimentel MI; Araújo-Silva M; Oliveira RV; Carmo CN; Valete-Rosalino CM
J Laryngol Otol; 2010 Oct; 124(10):1056-60. PubMed ID: 20537206
[TBL] [Abstract][Full Text] [Related]
28. [Acute pancreatitis during treatment with meglumine antimoniate (Glucantime)].
Barthet M; Brunet P; Bernard JC; Dussol B; Rodor F; Jouglard J; Berland Y; Sahel J
Gastroenterol Clin Biol; 1994; 18(1):90-2. PubMed ID: 8187998
[No Abstract] [Full Text] [Related]
29. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
[TBL] [Abstract][Full Text] [Related]
30. Drug hypersensitivity syndrome induced by meglumine antimoniate.
Jeddi F; Caumes E; Thellier M; Jauréguiberry S; Mazier D; Buffet PA
Am J Trop Med Hyg; 2009 Jun; 80(6):939-40. PubMed ID: 19478253
[TBL] [Abstract][Full Text] [Related]
31. [Acute pancreatitis with a fatal evolution due to antimonials in patients with visceral leishmaniasis and HIV infection].
Santos J; Rivero A; Márquez M
An Med Interna; 2000 Oct; 17(10):562-3. PubMed ID: 11109659
[No Abstract] [Full Text] [Related]
32. [Torsades de pointes during treatment of leishmaniasis with meglumine antimoniate].
Castelló Viguer MT; Echánove Errazti I; Ridocci Soriano F; Esteban Esteban E; Atienza Fernández F; Cuesta Estellés G
Rev Esp Cardiol; 1999 Jul; 52(7):533-5. PubMed ID: 10439681
[TBL] [Abstract][Full Text] [Related]
33. Quantification of the response to miltefosine treatment for visceral leishmaniasis by QT-NASBA.
de Vries PJ; van der Meide WF; Godfried MH; Schallig HD; Dinant HJ; Faber WR
Trans R Soc Trop Med Hyg; 2006 Dec; 100(12):1183-6. PubMed ID: 16678871
[TBL] [Abstract][Full Text] [Related]
34. Mucosal Leishmania infantum infection.
Richter J; Hanus I; Häussinger D; Löscher T; Harms G
Parasitol Res; 2011 Sep; 109(3):959-62. PubMed ID: 21499751
[TBL] [Abstract][Full Text] [Related]
35. Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the southwestern region of Brazil.
Oliveira AL; Brustoloni YM; Fernandes TD; Dorval ME; Cunha RV; Bóia MN
Trop Doct; 2009 Jul; 39(3):180-2. PubMed ID: 19535762
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of visceral leishmaniasis: efficacy and limits of miltefosine].
Gangneux JP; Marty P
Sante; 2001; 11(4):257-8. PubMed ID: 11861203
[No Abstract] [Full Text] [Related]
37. Visceral leishmaniasis treatment in the Indian subcontinent: how to reach the most vulnerable.
Picado A; Rijal S; Sundar S; Boelaert M
Expert Rev Anti Infect Ther; 2012 Aug; 10(8):839-41. PubMed ID: 23030320
[No Abstract] [Full Text] [Related]
38. Treatment of cutaneous leishmaniasis in travelers 2009.
Blum JA; Hatz CF
J Travel Med; 2009; 16(2):123-31. PubMed ID: 19335813
[No Abstract] [Full Text] [Related]
39. Short-course of oral miltefosine for treatment of visceral leishmaniasis.
Sundar S; Makharia A; More DK; Agrawal G; Voss A; Fischer C; Bachmann P; Murray HW
Clin Infect Dis; 2000 Oct; 31(4):1110-3. PubMed ID: 11049800
[TBL] [Abstract][Full Text] [Related]
40. Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.
Mateo M; Maynard L; Vischer C; Bianciardi P; Miró G
Parasitol Res; 2009 Jul; 105(1):155-62. PubMed ID: 19238439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
